Overview of diabetic neuropathy and review of FDA-approved oral therapies
|Labbad, Ziad G.
|Love E, Garcia M, Labbad Z. Overview of diabetic neuropathy and review of FDA-approved oral therapies. The Foot & Ankle Online Journal [Internet]. 2020 Dec 31;13(4). Available from: https://faoj.org/2020/12/31/overview-of-diabetic-neuropathy-and-review-of-fda-approved-oral-therapies/ doi: 10.3827/faoj.2020.1304.0002
|Diabetic neuropathy is the most common complication of uncontrolled and chronic diabetes. Neuropathy is the result when the somatosensory system is compromised leaving patients with irreversible nerve damage. The continuity of this neuropathic pain may lead to disorders such as insomnia, depression, and anxiety. The cause of neuropathic pain cannot be treated, and current treatment management focuses on treating the symptoms. A review of current literature on diabetic neuropathy and of FDA approved oral therapies is performed to provide an extensive overview in order to reduce and prevent the progression of this disease. The epidemiology of diabetic neuropathy can be characterized by its prevalence and risk factors. Symmetric polyneuropathy is the most common type of diabetic neuropathy accounting for about 75% of affected patients and is divided into classes depending on the types of sensory fibers involved. Small fiber neuropathy is associated with burning, prickling pain due to non-painful stimuli or an exaggerated response to painful stimuli. Large fiber affected neuropathy involves numbness, tingling without pain, and loss of protective sensation. Besides lifestyle intervention and glucose control the first line medication for diabetic neuropathy is gabapentin, pregabalin and duloxetine. This literature review guide is dedicated to the millions suffering from diabetic neuropathy. Neuropathic pain is a chronic disorder that can impair a patient’s quality of life. The results of this literature review demonstrate a need for long-term research with advancing technologies on new medications to understand their specific effects and risks to patients.
|Faculty/ Researcher Works
|The Foot and Ankle Online Journal, Vol. 13
|International Foot & Ankle Foundation
|Attribution CC BY
|FDA warning for gabapentinoids
|Overview of diabetic neuropathy and review of FDA-approved oral therapies
|For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact email@example.com
|Temple University. School of Podiatric Medicine